Horizon Pharma’s (HZNP) “Buy” Rating Reaffirmed at Goldman Sachs Group Inc.

horizon-pharma8217s-hznp-8220buy8221-rating-reaffirmed-at-goldman-sachs-group-inc.jpg

Horizon Pharma Inc. (NASDAQ:HZNP)‘s stock had its “buy” rating reiterated by analysts at Goldman Sachs Group Inc. in a research report issued on Thursday. They currently have a $27.00 price objective on the biopharmaceutical company’s stock. Goldman Sachs Group Inc.’s target price would suggest a potential upside of 51.43% from the stock’s previous close.
Other research analysts also recently issued reports about the company. Jefferies Group reissued a “buy” rating on shares of Horizon Pharma in a report on Thursday. Mizuho reissued a “buy” rating and issued a $30.00 price target (up from $24.00) on shares of Horizon Pharma in a report on Wednesday, August 10th. Morgan Stanley raised Horizon Pharma from an “underweight” rating to an “equal weight” rating and set a $24.00 price target for the company in a report on Monday, July 11th. Vetr downgraded Horizon Pharma from a “strong-buy” rating to a “buy” rating and set a $18.42 price target for the company. in a report on Monday, May 30th. Finally, Zacks Investment Research raised Horizon Pharma from a “sell” rating to a “hold” rating in a report on Wednesday, May 11th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $29.38.
Horizon Pharma (NASDAQ:HZNP) traded up 0.79% on Thursday, hitting $17.97. The stock had a trading volume of 977,342 shares. The company’s market cap is $2.89 billion. Horizon Pharma has a 12 month low of $12.86 and a 12 month high of $32.34. The company has a 50-day moving average of $20.30 and a 200 day moving average of $17.52.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/08/horizon-pharmas-hznp-buy-rating-reaffirmed-at-goldman-sachs-group-inc.html

Horizon Pharma (NASDAQ:HZNP) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.12. The company earned $257.40 million during the quarter, compared to analyst estimates of $235.43 million. The company’s revenue was up 48.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.39 earnings per share. On average, analysts predict that Horizon Pharma will post $2.15 EPS for the current fiscal year.
In other Horizon Pharma news, EVP Jeffrey W. Sherman sold 2,900 shares of the business’s stock in a transaction on Tuesday, August 2nd. The stock was sold at an average price of $20.00, for a total transaction of $58,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Virinder Nohria sold 25,000 shares of the business’s stock in a transaction on Wednesday, June 15th. The stock was sold at an average price of $17.69, for a total value of $442,250.00. Following the transaction, the director now directly owns 189,836 shares in the company, valued at approximately $3,358,198.84. The disclosure for this sale can be found here. Company insiders own 2.10% of the company’s stock.
A number of institutional investors recently added to or reduced their stakes in the company. Highland Capital Management LP raised its position in Horizon Pharma by 108.0% in the fourth quarter. Highland Capital Management LP now owns 728,807 shares of the biopharmaceutical company’s stock worth $15,793,000 after buying an additional 378,473 shares during the period. Highbridge Capital Management LLC raised its position in Horizon Pharma by 2,861.5% in the fourth quarter. Highbridge Capital Management LLC now owns 1,651,116 shares of the biopharmaceutical company’s stock worth $35,780,000 after buying an additional 1,595,364 shares during the period. Stifel Financial Corp raised its position in Horizon Pharma by 22.1% in the fourth quarter. Stifel Financial Corp now owns 271,217 shares of the biopharmaceutical company’s stock worth $5,876,000 after buying an additional 49,063 shares during the period. Norges Bank bought a new position in Horizon Pharma during the fourth quarter worth $29,651,000. Finally, Rhenman & Partners Asset Management AB raised its position in Horizon Pharma by 37.0% in the first quarter. Rhenman & Partners Asset Management AB now owns 200,000 shares of the biopharmaceutical company’s stock worth $3,314,000 after buying an additional 54,000 shares during the period. 87.68% of the stock is currently owned by institutional investors.
About Horizon Pharma
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.

Receive News & Ratings for Horizon Pharma Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Horizon Pharma Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Be the first to comment on "Horizon Pharma’s (HZNP) “Buy” Rating Reaffirmed at Goldman Sachs Group Inc."

Leave a comment

Your email address will not be published.


*